![](https://ai-infra-summit.com/sites/default/files/styles/panopoly_image_square/public/speakers/mike_henry_headshot.jpg?itok=dpbp6pqw&c=cad298139fb6c00e4b496c58c5ed4fb9)
Mike Henry
![](https://ai-infra-summit.com/sites/default/files/styles/panopoly_image_square/public/speakers/ian_buck_headshot.jpg?itok=nz5ZbYlV&c=ab6b79ff93424bf1f7f5b20e52ce9e67)
Ian Buck
Ian Buck is vice president of NVIDIA's Accelerated Computing business unit, which includes all hardware and software product lines, third-party enablement, and marketing activities for GPU computing.
Buck joined NVIDIA in 2004 and created CUDA, which remains the established leading platform for accelerated-based parallel computing. Before joining NVIDIA, he was the development lead on Brook, which was the forerunner to generalized computing on GPUs.
Buck holds a Ph.D. in computer science from Stanford University and Bachelor of Science in computer science from Princeton University.
![](https://ai-infra-summit.com/sites/default/files/styles/panopoly_image_square/public/speakers/joy_chen.jpg?itok=bEQYj-pY&c=4b0f2c0a93ef199e2cdd144958827fed)
Joy Chen
![](https://ai-infra-summit.com/sites/default/files/styles/panopoly_image_square/public/speakers/malcolm_faers.png?itok=dIvKLSyv&c=b23b624f07f6692bead1b94b9b1e148b)
Malcolm Faers
![](https://ai-infra-summit.com/sites/default/files/styles/panopoly_image_square/public/speakers/chris_urch_photo.jpg?itok=6iQXWYmU&c=f32f2018bd86a5832da7884c877512ea)
Chris Urch
I did my first degree at Cambridge reading natural sciences and chemistry. I stayed at Cambridge to complete my PhD on organic synthesis with Professor Ian Fleming and then moved to the United States to undertake post-doctoral research, again on organic synthesis, with Professor Barry Trost. On returning to this country I started work for ICI Agrochemicals where I remained for 16 years as it became Zeneca and eventually Syngenta. During this time, I worked on both fungicide and insecticide research, principally sterol biosynthesis inhibitors and acetylcholine receptor agonists respectively.
After leaving Syngenta I joined Amura, a start-up company in Cambridge. Amura was developing antibiotics and in particular a β-lactamase inhibitor. I stayed with Amura for three years and then joined Glycoform for six years, a spin-out from the University of Oxford, where I was the Research Director. Glycoform researched various ways of improving pharmaceuticals by the use of sugars.
After leaving Glycoform I worked as a consultant, increasingly for Redag Crop Protection who are researching novel agrochemicals. Four years ago, I joined them full time as Head of Chemistry.